Expert panel okays Covishield, puts Covaxin on hold

In a huge step towards controlling the spread of the Coronavirus, India on Friday saw an expert panel clearing the Oxford Covid-19 vaccine, manufactured by the Serum Institute of India, even as a dry run of the inoculation programme is to be carried out in the country today. Continue Reading

Covid-19 vaccine: Serum Institute seeks emergency approval

The Serum Institute of India (SII) on Sunday became the first indigenous company to apply to the Drugs Controller General of India (DCGI) seeking emergency use authorisation for the Oxford Covid-19 vaccine in the country. Continue Reading

Covid-19: Russian vaccine to reach India next week

The first batch of Sputnik V vaccine for Covid-19 is likely to reach Kanpur’s Ganesh Shankar Vidyarthi Medical College from Russia by next week. Continue Reading

Covaxin: Bharat Biotech gets nod for phase 3 trials

Covaxin, the Coronavirus vaccine being developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR), has been cleared for the third phase of clinical trials. Continue Reading

Serum Institute gets nod to resume clinical trial of Covid vaccine

Drugs Controller General of India (DCGI) has given permission to Serum Institute of India to resume clinical trial of the Oxford Covid-19 vaccine candidate in the country. The earlier order of suspending any new recruitment for phase two and three trial has been revoked by DCGI Dr V G Somani. Continue Reading

Covid-19 vaccine trials stopped in India

Serum Institute of India (SII) has announced pausing clinical trials of AstraZeneca Oxford COVID-19 vaccine candidate in the country. Continue Reading

DGCI slaps notice on vaccine manufacturer

Drugs Controller General of India (DGCI) has issued a notice to the Serum Institute of India, which is manufacturing the Oxford University’s Covishield vaccine and will hold the phase 3 clinical trials in India from next week. Continue Reading

DCGI gives nod to Serum Institute for phase 2, 3 human clinical trials of Oxford vaccine

The Drugs Controller General of India (DCGI) has given nod to the Serum Institute of India (SII) for conducting phase 2 and 3 human clinical trials of the Oxford University developed Covid-19 vaccine candidate in the country. Continue Reading